Library Addressing-Challenges-with-Clinical-In-Use-Testing 
Pharmaceutical Technology
APRIL 14, 2023
Twist Bioscience has introduced Twist T-cell receptor (TCR) and Twist chimeric antigen receptor (CAR) libraries to facilitate the development of cell therapies. Researchers will now be able to speed up the creation of tailor-made libraries that can help in identifying and developing new cell therapies.
XTalks
NOVEMBER 7, 2022
Finding biomarkers for solid tumors used to be limited to tissue samples collected with a tissue biopsy. Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 18, 2023
Digital biomarkers promise to transform preventive medicine and clinical trials, but also raise issues of security, regulation and potential disparities in access. Deepika Khedekar, Clinical Trial Lead at IQVIA, provides an overview of the pros and cons, and suggests a possible solution. The potential of these digital tools is vast.
Drug Discovery World
MAY 25, 2023
The role of animal models in drug discovery following the FDA’s Modernisation Act was a theme that ran through the day, as many presentations looked at alternative model systems and addressed how we can reduce, reuse and recycle this type of research. Phenotyping, in contrast, can produce a hit/lead without a target.
pharmaphorum
SEPTEMBER 8, 2022
The article also outlines some of the challenges remaining to be tackled. In addition, radiopharmaceuticals can also be used in diagnostic imaging for the detection of cancer cells. Radiotherapy dates back more than a hundred years, yet it still remains a core part of cancer treatment today.
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.
Drug Discovery World
OCTOBER 4, 2022
The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. . billion, compared to $19.9
Expert insights. Personalized for you.
246 
Let's personalize your content